Ortoma: Further positive steps in the commercialization process - Redeye

Redeye comments on Ortoma’s announcement yesterday that they have submitted a supplemental 510(k) to the FDA regarding the Custom OTS™ Hip. This is positive and opens up the possibility of commercializing the custom version in the US during the second half of 2025. The initial milestone of USD 167t also indicates progress as per the agreement done in 2023.

Länk till analysen i sin helhet: https://www.redeye.se/research/1067740/ortoma-further-positive-steps-in-the-commercialization-process?utm_source=finwire&utm_medium=RSS